Table 1 Clinical characteristics of the discovery cohort. Values represent median ± standard deviation
Discovery cohort | All patients (n=14) | Crohn’s disease (n=4) | Ulcerative colitis (n=10) | Range | ||
|---|---|---|---|---|---|---|
Age (y) | 38.6 ± 13.6 | 32.3 ± 14.6 | 38 ± 11.8 | 16–62 | ||
BMI | 26.5 ± 6.8 | 27 ± 8.6 | 27 ± 7.1 | 19.7–38.9 | ||
Female sex, n (%) | 7 (50%) | 3 (75%) | 4 (40%) | Â | ||
Time since diagnosis, y | 14 ± 11 | 12 ± 6 | 16.1 ± 12 | 6–46 | ||
Smokers, n (%) | 3 (21.4%) | 1 (25%) | 2 (20%) | Â | ||
Prednisolone >20mg/day, n (%) | 2 (14.3%) | 1 (25%) | 1 (10%) | Â | ||
Budesonide, n (%) | 1 (7.1%) | 0 | 1 (10%) | Â | ||
Thiopurines, n (%) | 3 (21.4%) | 1 (25%) | 2 (20%) | Â | ||
Mesalamine therapy, n (%) | 12 (85.7%) | 2 (50%) | 9 (90%) | Â | ||
Clinical remission at week 14, n (%) | 7 (50%) | 3 (75%) | 4 (40%) | Â | ||
Remitters (R)/non-remitters (NR) | Â | R | NR | R | NR | Â |
C-reactive protein, baseline |  | 15.1±16.3 | 12.0 | 9.3±9.2 | 17.1±7.7 |  |
C-reactive protein, week 2 |  | 4.1±3.5 | 3.6 | 2.6±3.1 | 13.8±12.2 |  |
C-reactive protein, week 6 |  | 5.4±3.5 | 5.4 | 7.2±13.0 | 6.4±7.8 |  |
C-reactive protein, week 14 |  | 8.6±3.7 | 4.8 | 3.0±8.0 | 8.3±12.6 |  |
HBI/pMAYO score, baseline |  | 7±1 | 12 | 5.5±2.4 | 6±1.1 |  |
HBI/pMAYO score, week 2 |  | 6±0.6 | 12 | 3±2.4 | 5±1.8 |  |
HBI/pMAYO score, week 6 |  | 3±2.1 | 12 | 2.5±1.1 | 6±2.2 |  |
HBI/pMAYO score, week 14 |  | 1±2.1 | 12 | 0.75±0.9 | 6±1.2 |  |